Emil D. Kakkis - 01 Mar 2024 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role: President & CEO, Director
Signature: /s/ Karah Parschauer, attorney-in-fact
Issuer symbol: RARE
Transactions as of: 01 Mar 2024
Net transactions value: -$935,119
Form type: 4
Filing time: 05 Mar 2024, 20:06:18 UTC
Previous filing: 08 Feb 2024
Next filing: 07 Aug 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RARE	Common Stock	Award	$0	+38,428	+7.1%	$0.000000	578,198	01 Mar 2024	Direct	F1
transaction	RARE	Common Stock	Tax liability	$935,119	-17,417	-3%	$53.69	560,781	01 Mar 2024	Direct	F2
transaction	RARE	Common Stock	Award	$0	+3,132	+0.56%	$0.000000	563,913	01 Mar 2024	Direct	F3, F4
holding	RARE	Common Stock						2,263,985	01 Mar 2024	See FN	F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RARE	Stock Option (Right to Buy)	Award	$0	+70,094		$0.000000	70,094	01 Mar 2024	Common Stock	70,094	$53.69	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
F2	Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
F3	Represents shares of common stock which previously granted performance stock units were converted on March 1, 2024 upon certification of the performance metric.
F4	Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F5	By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009
F6	On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.